{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:19:08Z","timestamp":1795173548427,"version":"4.10.3"},"reference-count":20,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors associated with early progression (progression or death due to myeloma \u22643 months after CAR T-cell infusion) in patients treated with standard of care ide-cel at 11 US academic centers. Among 211 patients that received ide-cel, 43 patients had a progressive event \u22643 months of infusion. Patients with a history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, use of bridging therapy, Hispanic ethnicity, plasma cell leukemia and t(4;14) were more likely to progress \u22643 months of infusion (P&lt;0.05). Of these risk factors for early progression identified in univariate analyses, history of extramedullary disease, prior BCMA targeted therapy, elevated ferritin at lymphodepletion, plasma cell leukemia, and t(4;14) were associated with worse progression-free survival (PFS) in multivariable analysis. Presence of three or more of these factors had a significant negative impact on PFS (P&lt;0.001; median PFS for \u22653 factors, 3.2 months vs. 0 factors, 14.1 months). This study helps identify patients at high risk of early progression after CAR T-cell therapy who may benefit from specific interventions pre and post CAR T-cell therpy to improve outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2023.283888","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:37:11Z","timestamp":1697686631000},"page":"1514-1524","source":"Crossref","is-referenced-by-count":18,"title":["Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience"],"prefix":"10.3324","volume":"109","author":[{"given":"Hamza","family":"Hashmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Castaneda","family":"Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kalariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Anderson Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"60781","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.","DOI":"10.1038\/s41375-019-0435-7"},{"key":"60782","doi-asserted-by":"crossref","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020; 20(1):1-7.","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"60783","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"60784","doi-asserted-by":"crossref","unstructured":"Larry D., Anderson J, Munshi NC, Shah N. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021; 39(Suppl 15):8016.","DOI":"10.1200\/JCO.2021.39.15_suppl.8016"},{"key":"60785","doi-asserted-by":"crossref","unstructured":"Hansen DK, Sidana S, Peres LC. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023; 41(11):2087-2097.","DOI":"10.1200\/JCO.22.01365"},{"key":"60786","doi-asserted-by":"crossref","unstructured":"Shah N, Munshi NC, Berdeja JG. Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa Trial. Blood. 2021; 138(Suppl 1):1739.","DOI":"10.1182\/blood-2021-148375"},{"key":"60787","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"60788","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023; 41(6):1265-1274.","DOI":"10.1200\/JCO.22.00842"},{"key":"60789","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"60790","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"60791","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Ayuk FA, Klyuchnikov E, Wolschke C, Berger SC, Kr\u00f6ger N. Impact of high-risk disease on efficacy of CAR-T cell therapy for multiple myeloma: a meta-analysis of 723 patients. Haematologica. 2023; 108(10):2799-2802.","DOI":"10.3324\/haematol.2022.282510"},{"key":"60792","doi-asserted-by":"crossref","unstructured":"Peres LC, Oswald LB, Dillard C. Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy. Blood. 2022; 140(Suppl 1):623-625.","DOI":"10.1182\/blood-2022-158478"},{"key":"60793","doi-asserted-by":"crossref","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023; 13(1):117.","DOI":"10.1038\/s41408-023-00886-8"},{"key":"60794","doi-asserted-by":"crossref","unstructured":"Samur MK, Fulciniti M, Aktas Samur A. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021; 12(1):868.","DOI":"10.1038\/s41467-021-21177-5"},{"key":"60795","doi-asserted-by":"crossref","unstructured":"Locke FL, Rossi JM, Neelapu SS. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4(19):4898-4911.","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"60796","doi-asserted-by":"crossref","unstructured":"Villanueva R, Hansen DK, Tonseth RP. High metabolic tumor volume Is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma. Blood. 2022; 140(Suppl 1):10402-10404.","DOI":"10.1182\/blood-2022-167804"},{"key":"60797","doi-asserted-by":"crossref","unstructured":"Jain MD, Faramand R, Staedtke V. The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy. Blood. 2019; 134(Suppl 1):4105.","DOI":"10.1182\/blood-2019-127305"},{"key":"60798","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022; 12(3):45.","DOI":"10.1038\/s41408-022-00643-3"},{"key":"60799","doi-asserted-by":"crossref","unstructured":"Richard S, Lancman G, Rossi A. Extramedullary relapse post CAR-T. Blood. 2022; 140(Suppl 1):4301-4302.","DOI":"10.1182\/blood-2022-170119"},{"key":"60800","doi-asserted-by":"crossref","unstructured":"Jain MD, Jacobs MT, Nastoupil LJ. Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/ refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood. 2019; 134(Suppl 1):245.","DOI":"10.1182\/blood-2019-129624"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283888\/76177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283888\/76944","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11312\/76177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:04Z","timestamp":1794045904000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283888","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}